Niagen Bioscience (NAGE) Stock Forecast: StockMap's 2-Week Call
NAGE stock forecast: StockMap's model leans Underperform on Niagen Bioscience for the two weeks after the Nov 19 close, toward NAGE trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 5 two-week windows on NAGE since Aug 31; by chance, a call on the same dates was right 56% of the time.
Niagen Bioscience last closed at $1.87, -3.61% on the session.
Against the IVW growth benchmark the position is -1.28% over the forecast window.
Niagen Bioscience's market cap is $148.10M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).
Where NAGE sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 0 bullish and 15 bearish.
Agreement across those insights is 100%.
27 daily calls for NAGE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Niagen Bioscience in the 56th percentile on valuation and the 66th percentile on return on equity, where 100 is best.
Niagen Bioscience is classified under Consumer Staples / Personal Care Products.
StockMap tracks Niagen Bioscience as the 15th largest of the 26 companies it covers in the Personal Care Products industry, part of the Consumer Staples sector.
Across that group the current two-week reads are 10 Neutral, 8 Moderate Underperform, 5 Strong Underperform, 2 Moderate Outperform and 1 Strong Outperform.
On that composite Niagen Bioscience ranks 19th of 26 in the group, against a group median of -0.21.